Multivariate analysis of risk factors associated with late mortality by primary diagnosis
| Risk factors . | Relative risk . | 95% confidence interval . |
|---|---|---|
| Severe aplastic anemia (all-cause late mortality) | ||
| cGVHD | 4.0 | 1.1-14.1 |
| Females | 0.2 | 0.1-0.8 |
| Methotrexate for GVHD prophylaxis | 0.1 | 0.01-0.6 |
| Acute lymphoblastic leukemia | ||
| Relapse-related late mortality (high risk of relapse) | 3.4 | 1.2-9.8 |
| Nonrelapse-related late mortality | ||
| Methotrexate for GVHD prophylaxis | 0.2 | 0.04-0.6 |
| Cyclosporine for GVHD prophylaxis | 0.2 | 0.03-0.9 |
| Acute myeloid leukemia | ||
| Relapse-related late mortality | ||
| High risk of relapse | 7.8 | 1.7-35.0 |
| cGVHD | 5.8 | 1.7-2.0 |
| Nonrelapse-related late mortality | ||
| 18 to 45 y at HCT | 2.7 | 1.2-5.9 |
| Older than 45 y at HCT | 3.2 | 1.2-8.9 |
| cGVHD | 3.4 | 1.8-6.3 |
| Chronic myeloid leukemia | ||
| Relapse-related late mortality | ||
| 18 to 45 y at HCT | 5.1 | 1-26.1 |
| Older than 45 y at HCT | 15.4 | 1.6-144.8 |
| High risk of relapse | 3.3 | 1.2-9.1 |
| Nonrelapse-related late mortality (cGVHD) | 2.4 | 1.1-5.1 |
| Risk factors . | Relative risk . | 95% confidence interval . |
|---|---|---|
| Severe aplastic anemia (all-cause late mortality) | ||
| cGVHD | 4.0 | 1.1-14.1 |
| Females | 0.2 | 0.1-0.8 |
| Methotrexate for GVHD prophylaxis | 0.1 | 0.01-0.6 |
| Acute lymphoblastic leukemia | ||
| Relapse-related late mortality (high risk of relapse) | 3.4 | 1.2-9.8 |
| Nonrelapse-related late mortality | ||
| Methotrexate for GVHD prophylaxis | 0.2 | 0.04-0.6 |
| Cyclosporine for GVHD prophylaxis | 0.2 | 0.03-0.9 |
| Acute myeloid leukemia | ||
| Relapse-related late mortality | ||
| High risk of relapse | 7.8 | 1.7-35.0 |
| cGVHD | 5.8 | 1.7-2.0 |
| Nonrelapse-related late mortality | ||
| 18 to 45 y at HCT | 2.7 | 1.2-5.9 |
| Older than 45 y at HCT | 3.2 | 1.2-8.9 |
| cGVHD | 3.4 | 1.8-6.3 |
| Chronic myeloid leukemia | ||
| Relapse-related late mortality | ||
| 18 to 45 y at HCT | 5.1 | 1-26.1 |
| Older than 45 y at HCT | 15.4 | 1.6-144.8 |
| High risk of relapse | 3.3 | 1.2-9.1 |
| Nonrelapse-related late mortality (cGVHD) | 2.4 | 1.1-5.1 |